Parallel neuroinflammatory pathways to cerebrovascular burden and amyloid beta in Alzheimer's disease

Read full text
Authors: Batool Rizvi, Jenna N. Adams, Alison Bamford, Soyun Kim, Mithra Sathishkumar, Nicholas J. Tustison, Lisa Taylor, Nandita Tuteja, Liv McMillan, Bin Nan, Hengrui Cai, Yuritza Y. Escalante
+7 more Novelle J. Meza, Alyssa L. Harris, Rond Malhas, Adam M. Brickman, Mark Mapstone, Elizabeth A. Thomas, Michael A. Yassa
Cited by: 1
References: 34

Abstract

INTRODUCTION: Upstream neuroinflammation plays an important role in Alzheimer's disease (AD) but remains poorly understood. We tested whether two distinct neuroinflammatory markers are associated with cerebrovascular burden and amyloid beta (Aβ), and downstream, with plasma phosphorylated tau (p-tau217), medial temporal lobe (MTL) cortical and hippocampal atrophy, and memory deficits. METHODS: = 126). We used structural equation modeling to test whether plasma chitinase-3-like protein 1 (YKL-40) and glial fibrillary acidic protein (GFAP) contribute to distinct pathways. RESULTS: Higher plasma YKL-40 was associated with greater white matter hyperintensity (WMH), whereas higher plasma GFAP was related to increased 18F-florbetapir (FBP) standardized uptake value ratio (SUVR). Higher plasma GFAP, WMH, and FBP SUVR were independently associated with increased p-tau217. Plasma p-tau217 was associated with reduced MTL cortical thickness and hippocampal volume. Reduced hippocampal volume was related to worse memory. DISCUSSION: Future work can further investigate these neuroinflammatory pathways as potential therapeutic targets for AD.

Fields of Study & Subjects

Studies on Chitinases and Chitosanases Alzheimer's disease research and treatments Neuroinflammation and Neurodegeneration Mechanisms

Publication details

Journal / source
Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
Publisher
Wiley
Volume
18
Issue
3
Pages
e70415–e70415
Publication date
1 July 2026
Language
EN